Candidiasis drug discovery and development: New approaches targeting virulence for discovering and identifying new drugs

Expert Opinion on Drug Discovery

Volumn 8, Issue 9, 2013, Pages 1117-1126

  Pierce, Christopher G ^a   Lopez Ribot, Jose L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Antifungals; Biofilms; Candida albicans; Candidiasis; Filamentation; Targeting virulence; Virulence factors

Indexed keywords

ANTIFUNGAL AGENT; NEW DRUG; VIRULENCE FACTOR;

ANTIFUNGAL ACTIVITY; BIOFILM; CANDIDA ALBICANS; CANDIDIASIS; DRUG SCREENING; DRUG TARGETING; FUNGAL VIRULENCE; PRIORITY JOURNAL; REVIEW;

EID: 84883004752     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.807245     Document Type: Review

References (103)

1. Brown GD, Denning DW, Gow NA, et al. Hidden killers: Human fungal infections. Sci Transl Med 2012;4(165):165rv13
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007;20(1):133-63 (Pubitemid 46167771)
3. Calderone RA. Candida and candidiasis. ASM Press, Washington; 2002
4. Lopez-Martinez R. Candidosis, a new challenge. Clin Dermatol 2010;28(2):178-84
5. Redding SW, Zellars RC, Kirkpatrick WR, et al. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol 1999;37(12):3896-900
6. Thompson GR III, Patel PK, Kirkpatrick WR, et al. Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109(4):488-95
7. Fidel PL Jr. Vaginal candidiasis: Review and role of local mucosal immunity. AIDS Patient Care STDS 1998;12(5):359-66
8. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999;29(2):239-44 (Pubitemid 29380177)
9. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37(9):1172-7 (Pubitemid 37372504)
10. Pappas PG, Kauffman CA, Andes D, et al Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-35
11. Pittet D, Li N, Woolson RF, et al. Microbiological factors influencing the outcome of nosocomial bloodstream infections: A 6-year validated, population-based model. Clin Infect Dis 1997;24(6):1068-78 (Pubitemid 27249003)
12. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 2005;41(9):1232-9 (Pubitemid 41532664)
13. Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002;5(1):26-34 (Pubitemid 34160368)
14. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, et al. An insight into the antifungal pipeline: Selected new molecules and beyond. Nat Rev Drug Discov 2010;9(9):719-27
15. Odds FC, Brown AJ, Gow NA. Antifungal agents: Mechanisms of action. Trends Microbiol 2003;11(6):272-9 (Pubitemid 36725017)
16. Perea S, Lopez-Ribot JL, Kirkpatrick WR, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001;45(10):2676-84 (Pubitemid 32906656)
17. Kuhn DM, Ghannoum MA. Candida biofilms: Antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 2004;5(2):186-97
18. Ramage G, Vande Walle K, Wickes BL, et al. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001;45(9):2475-9 (Pubitemid 32801898)
19. Hernandez S, Lopez-Ribot JL, Najvar LK, et al. Caspofungin resistance in Candida albicans: Correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004;48(4):1382-3 (Pubitemid 38405501)
20. Wiederhold NP, Grabinski JL, Garcia-Effron G, et al. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother 2008;52(11):4145-8
21. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: A new paradigm for antimicrobial therapy. Nat Chem Biol 2007;3(9):541-8 (Pubitemid 47294400)
22. Gauwerky K, Borelli C, Korting HC. Targeting virulence: A new paradigm for antifungals. Drug Discov Today 2009;14(3-4):214-22
23. Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003;1(1):17-24
24. Casadevall A, Pirofski LA. Microbial virulence results from the interaction between host and microorganism. Trends Microbiol 2003;11(4):157-8; author reply 58-9
25. Casadevall A, Pirofski L. Host-pathogen interactions: The attributes of virulence. J Infect Dis 2001;184(3):337-44; Epub 2001 Jun 27 (Pubitemid 32662181)
26. Casadevall A, Pirofski LA. Host-pathogen interactions: Basic concepts of microbial commensalism, colonization, infection, and disease. Infect Immun 2000;68(12):6511-18 (Pubitemid 32463348)
27. Casadevall A, Pirofski LA. What is a pathogen? Ann Med 2002;34(1):2-4 (Pubitemid 34454415)
28. Calderone RA, Cihlar RL. Fungal pathogenesis. Principles and Clinical Applications. Marcel Decker, New York; 2002
29. Calderone RA, Fonzi WA. Virulence factors of Candida albicans. Trends Microbiol 2001;9(7):327-35 (Pubitemid 32575277)
30. Davis D. Adaptation to environmental pH in Candida albicans and its relation to pathogenesis. Curr Genet 2003;44(1):1-7; Epub 2003 Jun 18
31. Soll DR. Candida commensalism and virulence: The evolution of phenotypic plasticity. Acta Trop 2002;81(2):101-10 (Pubitemid 34093800)
32. Chaffin WL, Lopez-Ribot JL, Casanova M, et al. Cell wall and secreted proteins of Candida albicans: Identification, function, and expression. Microbiol Mol Biol Rev 1998;62(1):130-80 (Pubitemid 28130799)
33. Cutler JE. Putative virulence factors of Candida albicans. Annu Rev Microbiol 1991;45:187-218 (Pubitemid 21903789)
34. Odds FC, Gow NA, Brown AJ. Fungal virulence studies come of age. Genome Biol 2001;2:1009.1-4
35. Sudbery PE. Growth of Candida albicans hyphae. Nat Rev Microbiol 2011;9(10):737-48
36. Banerjee M, Thompson DS, Lazzell A, et al. UME6, a novel filament-specific regulator of Candida albicans hyphal extension and virulence. Mol Biol Cell 2008;19(4):1354-65 (Pubitemid 351805091)
37. Braun BR, Johnson AD. Control of filament formation in Candida albicans by the transcriptional repressor TUP1. Science 1997;277(5322):105-9 (Pubitemid 27450657)
38. Braun BR, Johnson AD. TUP1, CPH1 and EFG1 make independent contributions to filamentation in Candida albicans. Genetics 2000;155(1):57-67 (Pubitemid 30257110)
39. Braun BR, Kadosh D, Johnson AD. NRG1, a repressor of filamentous growth in C.albicans, is down-regulated during filament induction. Embo J 2001;20(17):4753-61 (Pubitemid 32848628)
40. Carlisle PL, Banerjee M, Lazzell A, et al. Expression levels of a filament-specific transcriptional regulator are sufficient to determine Candida albicans morphology and virulence. Proc Natl Acad Sci USA 2009;106(2):599-604
41. Ernst JF. Transcription factors in Candida albicans - environmental control of morphogenesis. Microbiology 2000;146(Pt 8):1763-74
42. Murad AM, Leng P, Straffon M, et al. NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in Candida albicans. Embo J 2001;20(17):4742-52 (Pubitemid 32848627)
43. Saville SP, Lazzell AL, Monteagudo C, et al. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell 2003;2(5):1053-60 (Pubitemid 37298719)
44. Zheng X, Wang Y. Hgc1, a novel hypha-specific G1 cyclin-related protein regulates Candida albicans hyphal morphogenesis. Embo J 2004;23(8):1845-56 (Pubitemid 38649647)
45. MacCallum DM, Odds FC. Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 2005;48(3):151-61 (Pubitemid 40592846)
46. Phan QT, Belanger PH, Filler SG. Role of hyphal formation in interactions of Candida albicans with endothelial cells. Infect Immun 2000;68(6):3485-90 (Pubitemid 30340448)
47. Lo HJ, Kohler JR, DiDomenico B, et al. Nonfilamentous C. albicans mutants are avirulent. Cell 1997;90(5):939-49 (Pubitemid 27381632)
48. Chaturvedi AK, Lazzell AL, Saville SP, et al. Validation of the tetracycline regulatable gene expression system for the study of the pathogenesis of infectious disease. PLoS One 2011;6(5):e20449
49. Nakayama H, Mio T, Nagahashi S, et al. Tetracycline-regulatable system to tightly control gene expression in the pathogenic fungus Candida albicans. Infect Immun 2000;68(12):6712-19 (Pubitemid 32463375)
50. Saville SP, Lazzell AL, Bryant AP, et al. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Chemother 2006;50(10):3312-16 (Pubitemid 44527503)
51. Chang W, Li Y, Zhang L, et al. Retigeric acid B attenuates the virulence of Candida albicans via inhibiting adenylyl cyclase activity targeted by enhanced farnesol production. PLoS ONE 2012;7(7):e41624
52. Gibson J, Sood A, Hogan DA. Pseudomonas aeruginosa-Candida albicans interactions: Localization and fungal toxicity of a phenazine derivative. Appl Environ Microbiol 2009;75(2):504-13
53. Hogan DA, Vik A, Kolter R. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol 2004;54(5):1212-23 (Pubitemid 39578266)
54. Hornby JM, Jensen EC, Lisec AD, et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001;67(7):2982-92 (Pubitemid 33644762)
55. Joyner PM, Liu J, Zhang Z, et al. Mutanobactin A from the human oral pathogen Streptococcus mutans is a cross-kingdom regulator of the yeast-mycelium transition. Org Biomol Chem 2010;8(24):5486-9
56. Martins M, Henriques M, Azeredo J, et al. Morphogenesis control in Candida albicans and Candida dubliniensis through signaling molecules produced by planktonic and biofilm cells. Eukaryot Cell 2007;6(12):2429-36
57. Murzyn A, Krasowska A, Stefanowicz P, et al. Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth, adhesion and biofilm formation. PLoS One 2010;5(8):e12050
58. Zhang L, Chang W, Sun B, et al. Bisbibenzyls, a new type of antifungal agent, inhibit morphogenesis switch and biofilm formation through upregulation of DPP3 in Candida albicans. PLoS ONE 2011;6(12):e28953
59. Midkiff J, Borochoff-Porte N, White D, et al. Small molecule inhibitors of the Candida albicans budded-to-hyphal transition act through multiple signaling pathways. PLoS One 2011;6(9):e25395
60. Toenjes KA, Munsee SM, Ibrahim AS, et al. Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 2005;49(3):963-72 (Pubitemid 40327711)
61. Shareck J, Belhumeur P. Modulation of morphogenesis in Candida albicans by various small molecules. Eukaryot Cell 2011;3:3
62. Navarathna DH, Hornby JM, Krishnan N, et al. Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans. Infect Immun 2007;75(4):1609-18 (Pubitemid 46559424)
63. Martins M, Lazzell AL, Lopez-Ribot JL, et al. Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis. J Basic Microbiol 2012;52(4):487-91
64. Cheng SC, Joosten LA, Kullberg BJ, et al. Interplay between Candida albicans and the mammalian innate host defense. Infect Immun 2012;80(4):1304-13
65. Netea MG, Brown GD, Kullberg BJ, et al. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008;6(1):67-78 (Pubitemid 350286221)
66. Fidel PL Jr, Barousse M, Espinosa T, et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 2004;72(5):2939-46 (Pubitemid 38542424)
67. Moyes DL, Runglall M, Murciano C, et al. A biphasic innate immune MAPK response discriminates between the yeast and hyphal forms of Candida albicans in epithelial cells. Cell Host Microbe 2010;8(3):225-35
68. Lorenz MC, Fink GR. The glyoxylate cycle is required for fungal virulence. Nature 2001;412(6842):83-6 (Pubitemid 32851514)
69. MacCallum DM, Castillo L, Brown AJ, et al. Early-expressed chemokines predict kidney immunopathology in experimental disseminated Candida albicans infections. PLoS One 2009;4(7):e6420
70. Costerton JW, Cheng KJ, Geesey GG, et al. Bacterial biofilms in nature and disease. Annu Rev Microbiol 1987;41:435-64
71. Donlan RM. Biofilms: Microbial life on surfaces. Emerg Infect Dis 2002;8(9):881-90 (Pubitemid 35000803)
72. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: A common cause of persistent infections. Science 1999;284(5418):1318-22 (Pubitemid 29289651)
73. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004;350(14):1422-9 (Pubitemid 38419996)
74. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15(2):167-93 (Pubitemid 34303762)
75. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004;17(2):255-67 (Pubitemid 38534029)
76. Nett J, Andes D. Candida albicans biofilm development, modeling a host-pathogen interaction. Curr Opin Microbiol 2006;9(4):340-5 (Pubitemid 44108718)
77. Ramage G, Martinez JP, Lopez-Ribot JL. Candida biofilms on implanted biomaterials: A clinically significant problem. FEMS Yeast Res 2006;6(7):979-86 (Pubitemid 44568854)
78. Ramage G, Mowat E, Jones B, et al. Our current understanding of fungal biofilms. Crit Rev Microbiol 2009;35(4):340-55
79. Ramage G, Saville SP, Thomas DP, et al. Candida biofilms: An update. Eukaryot Cell 2005;4(4):633-8 (Pubitemid 40600417)
80. Crump JA, Collignon PJ. Intravascular catheter-associated infections. Eur J Clin Microbiol Infect Dis 2000;19(1):1-8 (Pubitemid 30093374)
81. Raad I. Intravascular-catheter-related infections. Lancet 1998;351(9106):893-8 (Pubitemid 28121188)
82. Viudes A, Peman J, Canton E, et al. Candidemia at a tertiary-care hospital: Epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 2002;21(11):767-74 (Pubitemid 35435697)
83. Chandra J, Kuhn DM, Mukherjee PK, et al. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol 2001;183(18):5385-94 (Pubitemid 32802612)
84. Nobile CJ, Mitchell AP. Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 2006;8(9):1382-91 (Pubitemid 44194572)
85. Uppuluri P, Chaturvedi AK, Srinivasan A, et al. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog 2010;6(3):e1000828
86. Ramage G, Saville SP, Wickes BL, et al. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002;68(11):5459-63 (Pubitemid 35265681)
87. Ramage G, VandeWalle K, Lopez-Ribot JL, et al. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett 2002;214(1):95-100 (Pubitemid 35245528)
88. Lopez-Ribot JL. Candida albicans biofilms: More than filamentation. Curr Biol 2005;15(12):R453-5
89. Nobile CJ, Fox EP, Nett JE, et al. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 2012;148(1-2):126-38
90. Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 2008;62(1):153-5 (Pubitemid 351865889)
91. Redding S, Bhatt B, Rawls HR, et al. Inhibition of Candida albicans biofilm formation on denture material. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107(5):669-72
92. Pierce CG, Uppuluri P, Tristan AR, et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc 2008;3(9):1494-500
93. Robbins N, Uppuluri P, Nett J, et al. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog 2011;7(9):e1002257
94. Uppuluri P, Nett J, Heitman J, et al. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 2008;52(3):1127-32 (Pubitemid 351358397)
95. Sardi JC, Scorzoni L, Bernardi T, et al. Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 2013;62(Pt 1):10-24
96. LaFleur MD, Lucumi E, Napper AD, et al. Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J Antimicrob Chemother 2011;66(4):820-6
97. Siles S, Srinivasan A, Pierce CP, et al. High-throughput screening of a collection of known pharmacologically active small compounds for the identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother 2013; [Epub ahead of print]
98. Martins M, Henriques M, Lopez-Ribot JL, et al. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses 2012;55(1):80-5
99. Martins M, Uppuluri P, Thomas DP, et al. Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia 2010;169(5):323-31
100. Srinivasan A, Uppuluri P, Lopez-Ribot J, et al. Development of a High-Throughput Candida albicans Biofilm Chip. PLoS ONE 2011;6(4):e19036
101. Braun BR, van Het Hoog M, d'Enfert C, et al. A human-curated annotation of the Candida albicans genome. PLoS Genet 2005;1(1):36-57
102. Saville SP, Thomas DP, Lopez-Ribot JL. Use of genome information for the study of the pathogenesis of fungal infections and the development of diagnostic tools. Rev Iberoam Micol 2005;22(4):238-41 (Pubitemid 43241085)
103. Letscher-Bru V, Herbrecht R. Caspofungin: The first representative of a new antifungal class. J Antimicrob Chemother 2003;51(3):513-21 (Pubitemid 36336143)